CD19 and hypophosphatemia: Herein we show that phosphorus repletion in patients with hypophosphatemia receiving anti-CD19 chimeric antigen receptor T-cell therapeutics was associated with significantly decreased immune effector cell–associated neurotoxicity syndrome (ICANS) incidence and symptom duration.